US Pandemic Relief Package Delivers OTC Industry Regulatory Wishes, Supplement Business Hopes
Executive Summary
It’s unlikely any industry stakeholder or FDA official expected a bill providing emergency economic relief to consumers, industries and health care services and facilities in response to a pandemic, including extensive support opportunities for small businesses, would be the vehicle that delivers on both of the industry’s congressional wishes. The supplement industry also looks for help in CARES Act.
You may also be interested in...
US FDA Checking Boxes On OTC Monograph Overhaul And In-Box For ACNU Switch Comments
“Who would have said that, looking forward two or three years ago, we would be where we are now?” says FDA OTC office director Theresa Michele. Monograph reform and introducing “additional conditions for nonprescription use” options for NDA OTCs each is a “real gamechanger.”
A New OTC Switch Pathway In US At Last: Acronym Isn’t The Only Thing That’s Changed
FDA proposes a novel pathway to permit OTC drugs to be marketed with additional controls to assure appropriate use, more than a decade after floating the idea. The pathway has a new name (“ACNU” not “NSURE”) and very different commercial dynamics.
A New OTC Pathway At Last: The Acronym Isn’t The Only Thing That’s Changed
The US FDA is proposing a novel pathway to permit OTC drugs to be marketed with some additional controls to assure appropriate use, more than a decade after floating the idea. The pathway has a new name (“ACNU” not “NSURE”) and very different commercial dynamics.